- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02597309
The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin (I-Can)
The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With ≥200 Units Per Day of U-500 Insulin
Study Overview
Detailed Description
Insulin resistance is one of the main causes of type 2 diabetes. Continuation of insulin resistance may lead to the failure of multiple oral antihyperglycemic medications in achieving glycemic control and the further requirement of escalading doses of insulin. On contrary, reduction of glucose toxicity and weight loss improves insulin sensitivity and may result in substantial reduction in insulin dose and %A1C.
U-500 insulin is the fastest-growing prescribed insulin in the US due to increased prevalence of severe obesity and extreme insulin resistance. Patients requiring high insulin doses of ≥200 units/day are the typical candidates for U-500 insulin. However, patients on such high doses of insulin rarely achieve target glycemic control.
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new antihyperglycemic medications approved for treatment of type 2 diabetes. Adding a SGLT-2 inhibitors to other antihyperglycemic medications was shown to reduce glucose toxicity, improve insulin sensitivity and reduce body weight. Consequently, daily insulin dose may be reduced without compromising glycemic control.
Canagliflozin is a sodium-glucose transporter subtype 2 (SGLT2) inhibitor that was approved by the FDA for the treatment of Type 2 diabetes in March, 2013. Canagliflozin, at the doses of 100mg and 300mg daily, improves blood sugar control by a novel mechanism which causes the kidneys to block reabsorption of about 50-80 grams of glucose. Canagliflozin lowers the renal threshold for glycosuria and causes excess glucose to be excreted in the urine.
The aim of this study is to evaluate the effect of adding a SGLT-2 inhibitor (namely Canagliflozin) on the dose of U-500 insulin required to achieve glycemic control in patients with type 2 diabetes. We hypothesize that adding Canagliflozin to patients treated with U-500 insulin may result in significant reduction in insulin dose due to improved insulin sensitivity and weight loss.
This is a double-blind, randomized, placebo-controlled clinical trial. Eligible subjects are patients with type 2 diabetes treated with ≥200 units per day of U-500 insulin with or without other antihyperglycemic medications. Participants will be randomized in a 1:1 ratio to one of the following 2 study arms.
I. Intervention Group: Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications. Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily. This dose will continue for 22 weeks.
II. Control Group: Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject with type 2 diabetes
- Subject is managed on ≥200 units of U-500 insulin plus or minus stable dose of oral antihyperglycemic medications for at least 3 months (dose of oral antihyperglycemic medications will remain stable during intervention)
- Subject is male or non-pregnant and non-lactating female
- Subject with BMI > 25 kg/m2
- Subject with A1C >7%
- Subject with serum potassium between 5-5.5 mEq/L
- If subject is on chronic medications such as anti-hypertensive, lipid-lowering medications, thyroid medication or hormonal therapy, the dose of these medications should be stable for at least three months prior to the screening visit. These medications will not be changed during the intervention period unless mandatory
Exclusion Criteria:
- Subject has history of renal disease (serum creatinine >1.5mg/dL or GFR <60 mL/min/1.73 m2).
- Subject has history of recurrent urinary tract infections
- Subject has history of urinary incontinence
- Subject has history of prostate hypertrophy
- Subject has history of cancer bladder or cancer prostate
- Subject has history of hematuria
- Subject using corticosteroid treatment, except inhaled or topical steroids
- Subject having an active malignancy (excluding the following dermal malignancies: basal cell carcinoma, squamous cell carcinoma, carcinoma in-situ of the cervix).
- Subject states that he/she had a recent cardiovascular event (e.g. myocardial infarction, stroke) ≤ six months prior to the screening visit; or stated that he/she had history of congestive heart failure.
- Subject has hepatic failure or had status post organ transplant
- Subject has any chronic, contagious or infectious diseases
- Subject has blood clotting or bleeding disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention Group
Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications.
Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily.
This dose will continue for 22 weeks.
|
Other Names:
|
Placebo Comparator: Control Group
Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in insulin recuirement
Time Frame: Twenty four weeks
|
Reduction in insulin requirements after adding canagliflozin with a difference in insulin dose of ≥30% between the 2 intervention groups
|
Twenty four weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHS# 2015-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes, Obesity
-
MedtronicNeuroCompletedSevere to Morbid Obesity and Type 2 DiabetesUnited States
-
Weill Medical College of Cornell UniversityNational Institute on Minority Health and Health Disparities (NIMHD); Cornell...RecruitingObesity, Childhood | Type2DiabetesUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of PatrasCompletedType 2 Diabetes | Morbid Obesity | Bariatric SurgeryGreece
-
Sykehuset i Vestfold HFCompletedType 2 Diabetes | Morbid ObesityNorway
-
Dasman Diabetes InstituteKuwait UniversityActive, not recruitingMorbid Obesity | Type2 Diabetes
-
Nemours Children's ClinicCompletedDiabetes Mellitus, Type 2 | Childhood ObesityUnited States
-
University Hospital, GasthuisbergCompletedType 2 Diabetes | Morbid ObesityBelgium
-
Imperial College LondonLondon North West Healthcare NHS TrustCompletedType 2 DiabetesUnited Kingdom
-
University of FloridaRecruiting
Clinical Trials on Canagliflozin
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type 2United States
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Research & Development, LLCCompletedDiabetes Mellitus, Type 2United States, Brazil
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type 2United States
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Research & Development, LLCCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 1 DiabetesUnited States
-
Janssen Research & Development, LLCThe George Institute for Global Health, AustraliaCompletedDiabetes Mellitus, Type 2 | AlbuminuriaAustralia, France, Italy, Poland, Ukraine, United Kingdom, United States, China, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Malaysia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Puerto... and more